Better Therapeutics, Inc.
Better Therapeutics, Inc.（BTTX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BTTX · 截至 2026年6月9日
活动摘要
买入笔数
12
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Better Therapeutics, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
BTTX 季度内部人买卖趋势
BTTX 内幕交易卖出 · BTTX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
BTTX 高管卖出股份 · BTTX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Feb 9, 2024 | PERRY DAVID P Executive Chairman · Director | Award | 839,895 | $160K | Form 4 |
| Jan 9, 2024 | PERRY DAVID P Executive Chairman · Director | Award | 1,471,453 | $250K | Form 4 |
| Dec 18, 2023 | PERRY DAVID P Executive Chairman · Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | Carmona Richard H Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | LAVIZZO-MOUREY RISA J Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | Wynholds Kristin Chief Product Officer | Award | 25,362 | — | Form 4 |
| Dec 18, 2023 | Parker Geoffrey M. Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | Armanino Andrew J. Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | Miller Leslie A. PAO | Award | 3,587 | — | Form 4 |
| Dec 18, 2023 | Granger Elder Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | KARBE FRANK CEO · Director | Award | 62,500 | — | Form 4 |
| Dec 18, 2023 | Berman Mark A. Chief Medical Officer | Award | 25,362 | — | Form 4 |
| Jul 27, 2023 | PERRY DAVID P Executive Chairman · Director | Purchase | 1,233,045 | $900K | Form 4 |
| Jul 27, 2023 | Berman Mark A. Chief Medical Officer | Purchase | 54,802 | $40K | Form 4 |
| Jul 27, 2023 | Armanino Andrew J. Director | Purchase | 274,010 | $200K | Form 4 |
| Jul 27, 2023 | Granger Elder Director | Purchase | 34,251 | $25K | Form 4 |
| Jul 27, 2023 | KARBE FRANK CEO · Director | Purchase | 137,005 | $100K | Form 4 |
| Jul 27, 2023 | Parker Geoffrey M. Director | Purchase | 685,025 | $500K | Form 4 |
| May 16, 2023 | Granger Elder Director | Purchase | 600 | $520 | Form 4 |
| Apr 5, 2023 | Heinen Mark CFO | Award | 54,000 | — | Form 4 |
| Apr 5, 2023 | Wynholds Kristin Chief Product Officer | Award | 101,450 | — | Form 4 |
| Apr 5, 2023 | Berman Mark A. Chief Medical Officer | Award | 101,450 | — | Form 4 |
| Apr 10, 2023 | PERRY DAVID P See Remarks · Director | Purchase | 1,333,333 | $1.10M⚡ | Form 4 |
| Apr 10, 2023 | PERRY DAVID P See Remarks · Director | Purchase | 3,636,364 | $3.00M⚡ | Form 4 |
| Apr 10, 2023 | KARBE FRANK See Remarks · Director | Purchase | 242,424 | $200K | Form 4 |
PERRY DAVID P
Executive Chairman · Director
日期
Feb 9
股数
839,895
均价
$0.19
总金额
$160K
PERRY DAVID P
Executive Chairman · Director
日期
Jan 9
股数
1,471,453
均价
$0.17
总金额
$250K
PERRY DAVID P
Executive Chairman · Director
日期
Jul 27
股数
1,233,045
均价
$0.73
总金额
$900K
PERRY DAVID P
See Remarks · Director
日期
Apr 10
股数
1,333,333
均价
$0.82
总金额
$1.10M ⚡
PERRY DAVID P
See Remarks · Director
日期
Apr 10
股数
3,636,364
均价
$0.82
总金额
$3.00M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BTTX 内幕交易
BTTX 内幕交易
Better Therapeutics, Inc.（BTTX）内幕交易数据来源于公司内部人（包括BTTX）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。BTTX内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Better Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BTTX 内幕交易 · 5个问题Better Therapeutics, Inc.（BTTX）的内部人包括高管和董事，如BTTX等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026